Extended Abstracts

Flat dose (175 mg/weekly) paclitaxel: pharmacokinetics and clinical implications

K. Mross, N. Holl

Price
42.00 $

Extended Abstracts

Preface

K. Mross

Price
42.00 $

Extended Abstracts

The influence of liver metastases on the pharmacokinetics of doxorubicin – a population-based pharmacokinetic project of the CESAR-APOH

H.J. Müller, R.E. Port, M. Grubert, R.A. Hilger, M. Scheulen and K. Mross

Price
42.00 $

Extended Abstracts

Drug-drug interaction pharmacokinetic study with the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with irinotecan (CPT-11) in patients with solid tumors

K. Mross, S. Steinbild, F. Baas, M. Reil, P. Buss, S. Mersmann, D. Voliotis, B. Schwartz and E. Brendel

Price
42.00 $

2008 CESAR: Annual Meeting – Extended Abstracts

First-in-man and first-of-class-in-man clinical trials in oncology

K. Mross

Price
42.00 $

Extended Abstract

Clinical and pharmacokinetic study with liposomal doxorubicin (DL-1) in patients with advanced metastatic cancer – results from a phase-I study

K. Mross, T. Gierlich, B. Häring, W. März and C. Unger

Price
42.00 $

Extended Abstract

Serial measurements of pharmacokinetics, DCE-MRI, blood flow, PET and biomarkers in serum/plasma – what is a useful tool in clinical studies of anti-angiogenic drugs?

K. Mross, S. Fuxius and J. Drevs

Price
42.00 $

Extended Abstract

The influence of elevated liver function parameters on the pharmacokinetics of doxorubicin and epirubicin – a population based pharmacokinetic study of CESAR-APOH

H.J. Müller, M. Grubert, R. Hilger, H. Richly, R. Port, M. Scheulen and K. Mross

Price
42.00 $

Extended Abstract

Safety, efficacy and pharmacokinetics of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer

D. Strumberg, B. Schultheis, M.E. Scheulen, R.A. Hilger, J. Krauss, N. Marschner, F. Lordick, F. Bach, D. Reuter, L. Edler and K. Mross

Price
42.00 $

Extended Abstracts

Biomarker response on exposure to sunitinib and its primary metabolite (SU12662) in metastatic colorectal cancer patients

F. Kanefendt, A. Lindauer, M. Kinzig, D. Strumberg, M.E. Scheulen, K. Mross, R. Fischer, B. Moritz, F. Sörgel and U. Jaehde

Extended Abstracts

A preliminary report of a Phase II study of folinic acid, 5-fluorouracil, irinotecan (FOLFIRI) plus sunitinib with toxicity, efficacy, pharmacokinetics, biomarker, imaging data in patients with colorectal cancer with liver metastases as 1st line treatment

K. Mross, M. Büchert, U. Fasol, U. Jaehde, F. Kanefendt, D. Strumberg, J. Arends, J. Hense, B. Moritz, R. Fischer and M.E. Scheulen